AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8682015 — intervention group
Group type: COMPARATOR
Intervention: Matched group of 239 patients treated with alteplase in hospital
Number of subjects: 529
Study 1776536 — intervention group
Group type: EXPERIMENTAL
Intervention: NCI 'Quit for Good' materials
Number of subjects: 570
Study 1776536 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota 'Quit and Win' program
Number of subjects: 570
Study 1776536 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control condition
Number of subjects: 570
Study 6837336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (1.75 g/kg within 3 hours)
Number of subjects: 8
Study 6837336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (after 12 hours)
Number of subjects: 8
Study 31796891 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI > 24)
Number of subjects: 21435
Study 31796891 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 28)
Number of subjects: 21435
Study 31796891 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous change of BMI
Number of subjects: 21435
Study 29741634 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a alone
Number of subjects: 131
Study 29741634 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a in combination with lamivudine
Number of subjects: 131
Study 29741634 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a
Number of subjects: 131
Study 26721941 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 202
Study 26721941 — intervention group
Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 202
Study 26721941 — intervention group
Group type: COMPARATOR
Intervention: Increased mean number of watery stools at baseline
Number of subjects: 202
Study 26721941 — intervention group
Group type: COMPARATOR
Intervention: Mean number of watery stools
Number of subjects: 202
Study 24433230 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, scalable package providing two pregnancy visits and five post-natal home visits delivered by community health workers
Number of subjects: 30
Study 24433230 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30
Study 21840168 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice therapy
Number of subjects: 12
Study 19204231 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine, 0.05% emulsion
Number of subjects: 0
Study 21080348 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 21080348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) cyclophosphamide (CYC)
Number of subjects: 0
Study 21080348 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 0
Study 16000610 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy followed by surgery
Number of subjects: 392
Study 16000610 — intervention group
Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy
Number of subjects: 392
Study 12236626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg, days 1-7; 100 mg, days 8-14)
Number of subjects: 21
Study 12236626 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg, days 1-7; 40 mg, days 8-14)
Number of subjects: 21
Study 12236626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10612890 — intervention group
Group type: EXPERIMENTAL
Intervention: In-service training course (five-day course) for private and public primary physicians
Number of subjects: 0
Study 7478022 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct intraventricular infusion of urokinase
Number of subjects: 7
Study 1951164 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium glycerophosphate (CaGlyP)
Number of subjects: 16
Study 1951164 — intervention group
Group type: COMPARATOR
Intervention: Calcium gluconate plus KH2PO4 + K2HPO4 (CaGluc + P)
Number of subjects: 16
Study 7019270 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling, video replay, and counseling
Number of subjects: 15
Study 7019270 — intervention group
Group type: COMPARATOR
Intervention: Video replay and counseling
Number of subjects: 15
Study 29540885 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit gait training
Number of subjects: 32
Study 29540885 — intervention group
Group type: COMPARATOR
Intervention: Traditional gait training
Number of subjects: 32
Study 26621010 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Number of subjects: 50
Study 24727234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-30 mg)
Number of subjects: 63
Study 24727234 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (0.5-4 mg)
Number of subjects: 63
Study 23780423 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert system for critical event detection
Number of subjects: 35
Study 20733521 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% carbohydrate/1.2% protein supplement (MCP)
Number of subjects: 15
Study 20733521 — intervention group
Group type: COMPARATOR
Intervention: 6% carbohydrate supplement (CHO)
Number of subjects: 15
Study 18304172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 0
Study 18304172 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 0
Study 18304172 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus ointment 0.03% vs 0.1%
Number of subjects: 0
Study 16000988 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated SPECT
Number of subjects: 45
Study 16000988 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional echocardiography
Number of subjects: 45
Study 16000988 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated SPECT and two-dimensional echocardiography
Number of subjects: 45
Study 12874940 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (1 hour, once a week)
Number of subjects: 55
Study 12874940 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (1 hour, twice a week)
Number of subjects: 55
Study 12874940 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (1 hour, three times a week)
Number of subjects: 55
Study 12874940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 55
Study 10094949 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 38
Study 10094949 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 38
Study 8739172 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with non-resorbable ePTFE membranes and systemic antimicrobial therapy (ornidazole)
Number of subjects: 10
Study 8739172 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR) with non-resorbable ePTFE membranes and placebo
Number of subjects: 10
Study 8739172 — intervention group
Group type: EXPERIMENTAL
Intervention: No membrane and systemic antimicrobial therapy (ornidazole)
Number of subjects: 10
Study 8739172 — intervention group
Group type: COMPARATOR
Intervention: No membrane and placebo
Number of subjects: 10
Study 8739172 — intervention group
Group type: COMPARATOR
Intervention: Membrane without active drug
Number of subjects: 10
Study 8739172 — intervention group
Group type: COMPARATOR
Intervention: No membrane and no active drug
Number of subjects: 10
Study 1720833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (50 micrograms)
Number of subjects: 21
Study 1720833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6173518 — intervention group
Group type: EXPERIMENTAL
Intervention: SR clonidine (250 or 500 microgram)
Number of subjects: 0
Study 31834519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (2 g per day)
Number of subjects: 47
Study 31834519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 29858417 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced negative emotion (anger)
Number of subjects: 280
Study 29858417 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced negative emotion (anxiety)
Number of subjects: 280
Study 29858417 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced negative emotion (sadness)
Number of subjects: 280
Study 29858417 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 280
Study 29858417 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderating effects of cardiorespiratory fitness and habitual physical activity
Number of subjects: 280
Study 27280398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 60 mg
Number of subjects: 90
Study 27280398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 24847853 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.6 g protein · kg body weight(‐1) · d(‐1), 7% of energy from protein)
Number of subjects: 23
Study 24847853 — intervention group
Group type: COMPARATOR
Intervention: High-protein diet (2.2 g protein · kg body weight(‐1) · d(‐1), 25% of energy from protein)
Number of subjects: 23
Study 24847853 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein state
Number of subjects: 23
Study 22863669 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg) in subjects with mild renal impairment (50 to ≤ 80 mL/min)
Number of subjects: 25
Study 22863669 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg) in subjects with moderate renal impairment (30 to < 50 mL/min)
Number of subjects: 25
Study 22863669 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg) in subjects with severe renal impairment (5 to < 30 mL/min)
Number of subjects: 25
Study 22863669 — intervention group
Group type: COMPARATOR
Intervention: Memantine (10 mg) in subjects with normal renal function (> 80 mL/min)
Number of subjects: 25
Study 20620308 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based program
Number of subjects: 30
Study 20620308 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 17597552 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl (donepezil)
Number of subjects: 0
Study 17597552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15978498 — intervention group
Group type: EXPERIMENTAL
Intervention: Jendrássik maneuver (JM) facilitation during phasic wrist flexion
Number of subjects: 0
Study 15978498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic voluntary contraction of the homonymous muscle (soleus)
Number of subjects: 0
Study 15978498 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote flexor carpi radialis (FCR) contraction
Number of subjects: 0
Study 11833668 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival curves
Number of subjects: 451
Study 11833668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both survival and mortality curves
Number of subjects: 451
Study 11833668 — intervention group
Group type: COMPARATOR
Intervention: Mortality curves
Number of subjects: 451
Study 9606471 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus lamivudine 150 mg
Number of subjects: 254
Study 9606471 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus lamivudine 300 mg
Number of subjects: 254
Study 9606471 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 254
Study 7624263 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg administered 3 times/day for 7 days
Number of subjects: 10
Study 7624263 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 3 times/day for 7 days
Number of subjects: 10
Study 7624263 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 10
Study 7624263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2095605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (1 g/day for 4 days before and 4 days after surgery)
Number of subjects: 10
Study 2095605 — intervention group
Group type: COMPARATOR
Intervention: Control (no ambroxol treatment)
Number of subjects: 10
Study 869143 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 27
Study 869143 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 27
Study 869143 — intervention group
Group type: COMPARATOR
Intervention: Modified neuroleptoanaesthetic (NLA) technique
Number of subjects: 27
Study 31292226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 100 mg
Number of subjects: 6
Study 31292226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 250 mg
Number of subjects: 6
Study 31292226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate 400 mg
Number of subjects: 6
Study 31292226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (250 mg and 400 mg doses)
Number of subjects: 6
Study 28770946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial lysate
Number of subjects: 124
Study 28770946 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 124
Study 26482693 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity plus weight loss (PA+WL)
Number of subjects: 36
Study 26482693 — intervention group
Group type: COMPARATOR
Intervention: Physical activity plus successful aging (SA) education
Number of subjects: 36
Study 26482693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 36
Study 23564348 — intervention group
Group type: EXPERIMENTAL
Intervention: 600,000 IU (15,000 μg) i.m. cholecalciferol
Number of subjects: 40
Study 23564348 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU (7,500 μg) i.m. cholecalciferol
Number of subjects: 40
Study 23564348 — intervention group
Group type: COMPARATOR
Intervention: i.m. saline (control group)
Number of subjects: 40
Study 21214633 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical combination of levomenol and heparin (Group A)
Number of subjects: 278
Study 21214633 — intervention group
Group type: COMPARATOR
Intervention: Levomenol alone (Group B)
Number of subjects: 278
Study 21214633 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (Group C)
Number of subjects: 278
Study 21214633 — intervention group
Group type: COMPARATOR
Intervention: Cream base with no active substances (Group D)
Number of subjects: 278
Study 18954930 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) with glucose control
Number of subjects: 90
Study 18954930 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE at 48 hours
Number of subjects: 90
Study 18954930 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in NSE levels
Number of subjects: 90
Study 18954930 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE at 48 hours cut-off point
Number of subjects: 90
Study 18954930 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta NSE 24-48 hours cut-off point
Number of subjects: 90
Study 18954930 — intervention group
Group type: EXPERIMENTAL
Intervention: OHCA score
Number of subjects: 90
Study 17954367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan 10 mg/day and temocapril 2 mg/day
Number of subjects: 24
Study 17954367 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 10 mg/day
Number of subjects: 24
Study 17954367 — intervention group
Group type: COMPARATOR
Intervention: Temocapril 2 mg/day
Number of subjects: 24
Study 15076638 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 40
Study 15076638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11745583 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiation furthering intervention (experimental)
Number of subjects: 40
Study 11745583 — intervention group
Group type: COMPARATOR
Intervention: Directed problem-solving treatment program (control)
Number of subjects: 40
Study 11745583 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiation gainers (experimental group)
Number of subjects: 40
Study 11745583 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-month follow-up (experimental group)
Number of subjects: 40
Study 11745583 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-month follow-up (total sample differentiation gainers)
Number of subjects: 40
Study 9849800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue severity rated by patients using a 2-week diary and a fatigue questionnaire.
Number of subjects: 45
Study 9849800 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological disability measured by the Expanded Disability Status Scale (EDSS) and Neurological Rating Scale (NRS).
Number of subjects: 45
Study 9849800 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measures for cerebral abnormalities (T1- and T2-weighted).
Number of subjects: 45
Study 9849800 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional lesion load comparison between fatigued and non-fatigued subjects.
Number of subjects: 45
Study 9849800 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological progression rates and number of exacerbations in the 2-year period prior to assessment.
Number of subjects: 45
Study 7924121 — intervention group
Group type: EXPERIMENTAL
Intervention: Trefentanil
Number of subjects: 14
Study 7924121 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil
Number of subjects: 14
Study 7924121 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 14
Study 2520494 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (200 micrograms 4 times daily)
Number of subjects: 0
Study 2520494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 805950 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg etiroxate daily
Number of subjects: 59
Study 805950 — intervention group
Group type: COMPARATOR
Intervention: 6 mg dextrothyroxine (DT4) daily
Number of subjects: 59
Study 31186300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 3 mg
Number of subjects: 703
Study 31186300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 7 mg
Number of subjects: 703
Study 31186300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 703
Study 31186300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study 28832894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lipoma plane (ULP) block (Group A)
Number of subjects: 48
Study 25259467 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional race-specific warm-up (RSWU)
Number of subjects: 18
Study 25259467 — intervention group
Group type: COMPARATOR
Intervention: Upper-body PAP (UBPAP)
Number of subjects: 18
Study 25259467 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PAP warm-up (CPAP)
Number of subjects: 18
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Any DMARD
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic DMARD
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nonbiologic and biologic DMARDs
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbiologic DMARD
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids
Number of subjects: 1507
Study 23463543 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARDs
Number of subjects: 1507
Study 21219427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 75
Study 21219427 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hyperbaric air)
Number of subjects: 75
Study 21219427 — intervention group
Group type: EXPERIMENTAL
Intervention: Healers (patients who healed their ulcer)
Number of subjects: 75
Study 21219427 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-healers (patients who did not heal their ulcer)
Number of subjects: 75
Study 19271166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo leaf extract (GLE)
Number of subjects: 64
Study 19271166 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for diabetes
Number of subjects: 64
Study 16293960 — intervention group
Group type: EXPERIMENTAL
Intervention: Music during bronchoscopic examination
Number of subjects: 200
Study 16293960 — intervention group
Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 200
Study 12457302 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg, 300 mg, or 500 mg administered as a single dose or daily for 10 consecutive days
Number of subjects: 113
Study 12457302 — intervention group
Group type: EXPERIMENTAL
Intervention: PFA-100
Number of subjects: 113
Study 10527076 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week program of muscle strengthening and physical conditioning (3 days/week)
Number of subjects: 13
Study 10527076 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study 7594162 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (ergocalciferol)
Number of subjects: 32
Study 7594162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1659495 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 43
Study 1659495 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR
Number of subjects: 43
Study 7030855 — intervention group
Group type: COMPARATOR
Intervention: GIK (glucose-insulin-potassium)
Number of subjects: 100